DonaldCurley

Benzimidazoles have a unique mechanism of action. This single feature positions them as very promising anticancer therapeutics. They can be combined with other chemotherapeutic agents to increase their effectiveness against cancer and also delay or even prevent the development of resistance in these drugs. Furthermore, they exhibit great efficacy even when used as a monotherapy, which is not possible with most common chemotherapy drugs currently in use.

However, more research is needed to establish the proper dosage for different cancers and duration of treatment before benzmidazole can be introduced into clinical practice for cancer treatment.

All that said, it's important to realize that this has been studied primarily in mice and rats at this point – utilizing doses much higher than those typically prescribed. For now, however, it does appear that albendazole (and perhaps other benzmidazoles) may well have a promising future in cancer treatment – once the proper dosage is established by physicians.

Benzimidazoles are known to interfere with microtubule dynamics in a number of cells, including cancer cells. This interference results in a disruption in mitosis (cell division), which ultimately leads to the destruction of the cancer cell by apoptosis (programmed cell death). Microtubules are vital for cellular function; without them, the cancer cell cannot divide and therefore dies via differentiation or apoptosis.

Benzimidazoles also produce their effects on cancer cells independent of traditional chemotherapy agents like adriamycin, making them useful as an adjuvant therapy alongside these common chemotherapies.
https://www.fenbendazole.org/2019/1...g-shows-promising-result-in-cancer-treatment/